Targeted therapy with BRAF and MEK kinase inhibitors (BRAF/MEKi) represents an essential treatment option for metastatic melanoma patients with BRAF mutated disease after progression on immunotherapy. The gene discussed is BRAF; the disease is metastatic melanoma.